These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 26641142

  • 1. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
    Choi SE, Brignone M, Cho SJ, Jeon HJ, Jung R, Campbell R, Francois C, Milea D.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
    Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-Setälä M, Danchenko N, Koponen H, Kolasa K.
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
    [Abstract] [Full Text] [Related]

  • 3. The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.
    Lomas J, Llewellyn A, Soares M, Simmonds M, Wright K, Eastwood A, Palmer S.
    Pharmacoeconomics; 2016 Sep; 34(9):901-12. PubMed ID: 27289476
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
    Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, Cure S, Danchenko N.
    J Affect Disord; 2017 Aug 15; 218():291-298. PubMed ID: 28478358
    [Abstract] [Full Text] [Related]

  • 5. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr 15; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 6. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A.
    Curr Med Res Opin; 2020 May 15; 36(5):875-882. PubMed ID: 31990207
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
    Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb 15; 21(1):29-42. PubMed ID: 33307885
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
    Nordström G, Danchenko N, Despiegel N, Marteau F.
    Value Health; 2012 Feb 15; 15(2):231-9. PubMed ID: 22433753
    [Abstract] [Full Text] [Related]

  • 9. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T.
    J Med Assoc Thai; 2012 May 15; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
    Brignone M, Diamand F, Painchault C, Takyar S.
    Curr Med Res Opin; 2016 May 15; 32(2):351-66. PubMed ID: 26637048
    [Abstract] [Full Text] [Related]

  • 11. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP.
    CNS Drugs; 2015 Aug 15; 29(8):695-712. PubMed ID: 26293743
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 15; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
    Annemans L, Brignone M, Druais S, De Pauw A, Gauthier A, Demyttenaere K.
    Pharmacoeconomics; 2014 May 15; 32(5):479-93. PubMed ID: 24554474
    [Abstract] [Full Text] [Related]

  • 14. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
    Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, Armada Peláez B.
    Rev Psiquiatr Salud Ment; 2016 May 15; 9(2):87-96. PubMed ID: 26475204
    [Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
    Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E.
    Eur Neuropsychopharmacol; 2017 Aug 15; 27(8):773-781. PubMed ID: 28663124
    [Abstract] [Full Text] [Related]

  • 16. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
    Nguyen KH, Gordon LG.
    Value Health; 2015 Jul 15; 18(5):597-604. PubMed ID: 26297087
    [Abstract] [Full Text] [Related]

  • 17. A pharmacoeconomic evaluation of major depressive disorder (Italy).
    Casciano J, Arikian S, Tarride JE, Doyle JJ, Casciano R.
    Epidemiol Psichiatr Soc; 1999 Jul 15; 8(3):220-31. PubMed ID: 10638040
    [Abstract] [Full Text] [Related]

  • 18. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep 15; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
    Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G.
    J Affect Disord; 2018 Mar 01; 228():1-12. PubMed ID: 29197738
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN, Welch MJ, Kozel FA, Demitrack MA, Nahas Z.
    Adv Ther; 2009 Mar 01; 26(3):346-68. PubMed ID: 19330495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.